Skip to main content
Assets
Sanofi logo
SAN.PAR
Sanofi
Health Care · Pharmaceuticals

French multinational pharmaceutical company developing vaccines, treatments for diabetes, cardiovascular diseases, oncology, and rare diseases.

HQ: FranceListed: France

Historical AI Forecasts

Audit every published iPulse AI forecast batch and immutable historical research document for Sanofi.

Historical AI Forecasts

Sanofi S.A. (SAN.PAR) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 11 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 3 May 2026Deep analysis 3 May 2026

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
Elon Musk AI advisor icon

Elon Musk AI

The Visionary FrameworkAI Researcher

Model rating

Buy

5-Year Return Est.

+129.0%

Includes 4.17% annual net dividend contribution

1. Investment Thesis — Base Case

Sanofi executes a brutal but mathematically necessary pivot, evolving from a legacy dinosaur into a first-principles, AI-driven biopharma. Garijo takes over and immediately trims the fat, killing doomed legacy trials and reallocating capital entirely toward the AI/mRNA platform. The €10B Opella cash and Blueprint acquisition start generating high-margin rare disease revenue, easing the concentration panic. The Q4 formulation shows early clinical promise, pushing the catastrophic LOE narrative out to 2045. Meanwhile, the environment makes Sanofi's dividend and defensive cash flows irresistible to fleeing tech/consumer sectors. The stock reprices from a melting ice cube to an AI-enabled cash machine.

  • Garijo implements ruthless , stopping R&D cash-burn on NGMI legacy assets.
  • RiboNN and CodonBERT structurally reduce mRNA design times, proving the AI thesis.
  • Q4 trials succeed, legally extending the patent moat and preserving the €16B+ .
  • The €15B M&A war chest is weaponized to acquire distressed, high-quality biotech assets.
  • forces a rotation into high-yield, inelastic healthcare equities, providing a relentless bid.

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in EUR.65.5188.27111.03133.79156.55Apr 2021Oct 2023Apr 2026Oct 2028Apr 2031Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in EUR.
View chart values
Historical prices and published forecast — published chart values
SeriesDateValue (EUR)
Observed price2021-04-2887.0
Observed price2021-05-0683.8
Observed price2021-05-2287.7
Observed price2021-06-0385.0
Observed price2021-06-1188.4
Observed price2021-07-0586.4
Observed price2021-07-1388.3
Observed price2021-08-0685.8
Observed price2021-08-1487.2
Observed price2021-08-2289.2
Observed price2021-09-1182.0
Observed price2021-09-1580.9
Observed price2021-10-0983.9
Observed price2021-10-1782.8
Observed price2021-11-0289.1
Observed price2021-11-1089.3
Observed price2021-11-3083.4
Observed price2021-12-0884.1
Observed price2022-01-0188.7
Observed price2022-01-0587.8
Observed price2022-01-2993.3
Observed price2022-02-1892.5
Observed price2022-02-2691.3
Observed price2022-03-0689.3
Observed price2022-03-2293.5
Observed price2022-03-3093.1
Observed price2022-04-11106
Observed price2022-04-27103
Observed price2022-05-0996.5
Observed price2022-05-25104
Observed price2022-06-1494.2
Observed price2022-06-2295.5
Observed price2022-07-12100
Observed price2022-07-2098.8
Observed price2022-08-1384.9
Observed price2022-08-1781.7
Observed price2022-08-2580.5
Observed price2022-09-1880.8
Observed price2022-09-2677.4
Observed price2022-10-2080.8
Observed price2022-11-0587.1
Observed price2022-11-1383.5
Observed price2022-11-2988.2
Observed price2022-12-1988.8
Observed price2022-12-2391.0
Observed price2023-01-1691.7
Observed price2023-01-2889.6
Observed price2023-02-0585.4
Observed price2023-02-2589.7
Observed price2023-03-0189.0
Observed price2023-03-2597.8
Observed price2023-04-0299.6
Observed price2023-04-22103
Observed price2023-04-26103
Observed price2023-04-3099.0
Observed price2023-05-24101
Observed price2023-06-1393.9
Observed price2023-07-0398.3
Observed price2023-07-1593.7
Observed price2023-07-2398.1
Observed price2023-08-0493.9
Observed price2023-08-1696.3
Observed price2023-09-09101
Observed price2023-09-29101
Observed price2023-10-07103
Observed price2023-10-11103
Observed price2023-10-2781.4
Observed price2023-11-1684.8
Observed price2023-11-2486.4
Observed price2023-12-0686.1
Observed price2023-12-3089.9
Observed price2024-01-0391.9
Observed price2024-01-1595.3
Observed price2024-01-3191.0
Observed price2024-02-1285.9
Observed price2024-03-0387.1
Observed price2024-03-2389.3
Observed price2024-03-2791.1
Observed price2024-04-1686.8
Observed price2024-05-1094.3
Observed price2024-05-1889.7
Observed price2024-06-0791.1
Observed price2024-06-1587.8
Observed price2024-06-1986.8
Observed price2024-07-1393.1
Observed price2024-07-1792.0
Observed price2024-07-2597.5
Observed price2024-08-1497.6
Observed price2024-09-07105
Observed price2024-09-11105
Observed price2024-10-05101
Observed price2024-10-09101
Observed price2024-11-0297.4
Observed price2024-11-0695.6
Observed price2024-11-1891.5
Observed price2024-12-1688.8
Observed price2024-12-2892.7
Observed price2025-01-1393.8
Observed price2025-01-25101
Observed price2025-01-29103
Observed price2025-02-14105
Observed price2025-02-26104
Observed price2025-03-06109
Observed price2025-03-26103
Observed price2025-04-1189.8
Observed price2025-05-0596.0
Observed price2025-05-1389.7
Observed price2025-05-2193.8
Observed price2025-06-0285.9
Observed price2025-06-3082.2
Observed price2025-07-1283.8
Observed price2025-07-2885.5
Observed price2025-08-0180.3
Observed price2025-08-2187.5
Observed price2025-09-0679.0
Observed price2025-09-2678.3
Observed price2025-10-0485.4
Observed price2025-10-1283.6
Observed price2025-10-2488.8
Observed price2025-11-0585.2
Observed price2025-11-1390.4
Observed price2025-12-0385.6
Observed price2025-12-1580.6
Observed price2026-01-0883.6
Observed price2026-01-2078.7
Observed price2026-02-0981.7
Observed price2026-02-1777.5
Observed price2026-03-0181.3
Observed price2026-03-1776.3
Observed price2026-03-2579.5
Observed price2026-04-0282.4
Observed price2026-04-2281.4
Observed price2026-05-0873.1
Observed price2026-06-0174.2
Observed price2026-06-0578.0
Observed price2026-06-2573.8
Observed price2026-07-1176.5
Observed price2026-07-2777.8
Observed price2026-08-0474.4
Observed price2026-08-1275.4
Observed price2026-08-2478.3
Observed price2026-09-1475.4
Observed price2026-09-1874.0
Published advisor forecast2026-04-3079.8
Published advisor forecast2026-07-3082.2
Published advisor forecast2026-10-3085.5
Published advisor forecast2027-01-3089.8
Published advisor forecast2027-04-3092.5
Published advisor forecast2027-07-3096.2
Published advisor forecast2027-10-3094.2
Published advisor forecast2028-01-3099.9
Published advisor forecast2028-04-30103
Published advisor forecast2028-07-30108
Published advisor forecast2028-10-30112
Published advisor forecast2029-01-30109
Published advisor forecast2029-04-30114
Published advisor forecast2029-07-30119
Published advisor forecast2029-10-30126
Published advisor forecast2030-01-30130
Published advisor forecast2030-04-30127
Published advisor forecast2030-07-30132
Published advisor forecast2030-10-30139
Published advisor forecast2031-01-30145
Published advisor forecast2031-04-30149

2. Scenarios & Signals

Bull case

The AI platform turns out to be entirely bussin. RiboNN and generative models flawlessly predict clinical efficacy, yielding two unexpected blockbusters in immunology and oncology by 2028. The Q4 patent is ironclad, and the Blueprint acquisition (Ayvakit) outperforms all future estimates.

  • AI engine discovers multiple novel targets that clear Phase 2 with unprecedented efficacy.
  • Garijo executes a masterful distressed-asset sweep of small biotechs crushed by the rate shock.
  • Sanofi becomes the first truly AI-native legacy pharma, expanding its multiple to tech-like levels.
  • expands exponentially as mRNA therapies conquer new disease vectors.

Bear case

Total boomer energy takes over. Garijo proves to be a purely financial operator who slashes the AI budget to protect the dividend, killing iteration velocity. The Q4 patent extension fails in court, making the 2031 revenue cliff a mathematical certainty.

  • fails to produce viable commercial therapies, proving it was just marketing hype.
  • The $9.5B Blueprint acquisition suffers severe integration friction and misses revenue targets.
  • destroy US margins, eroding the core business .
  • Sanofi slowly liquidates its assets while younger, AI-native biotechs eat its lunch.

Current crowd narrative

The noisy crowd thinks Sanofi is absolutely cooked. They see a legacy boomer pharma that just rug-pulled its CEO after a string of embarrassing clinical flops, hopelessly addicted to a single drug () facing a 2031 . Wall Street views it as a yield-trap dinosaur desperately spinning off consumer units (Opella) and overpaying for random biotechs (Blueprint) just to plug a sinking ship. The dominant narrative is pure copium and .

Alpha-gap assessment

The market is mathematically ignoring the physics-based restructuring of Sanofi's R&D engine. The €10B Opella spin-off cash buys them massive , while their UT Austin AI partnership (RiboNN) is secretly halving mRNA iteration cycles. Belén Garijo isn't here to manage a decline; she's here to stop the cash-burn on dead-end Phase 3s and scale the AI pipeline. The crowd prices a melting ice cube; the first-principles reality is an AI-accelerated cash machine currently trading at a massive discount.

Convergence catalyst

The mid-to-late 2026 pipeline update where new CEO Belén Garijo unveils her R&D restructuring plan, paired with Phase 2 data for the AI-discovered targets and the official start of the Q4 (four-week dosing) trials. This proves the AI engine works and the patent moat is secure.

Complete advisor preview locked

Unlock this report and every AI Advisor

Sign in to check your access, or upgrade to the Base plan to read this report and open every advisor.

Sign in to check accessView Base planReturn to latest AI Consensus